Failure or success of electronic search strategies to identify adverse effects data

Journal of the Medical Library Association

Volumn 100, Issue 2, 2012, Pages 130-134

  Golder, Su ^a   Loke, Yoon Kong ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLASSIFICATION; COHORT ANALYSIS; DOCUMENTATION; DRUG SURVEILLANCE PROGRAM; EVALUATION; HUMAN; INFORMATION RETRIEVAL; LIBRARY; LINGUISTICS; LITERATURE; MEDLINE; METHODOLOGY; UNITED STATES;

ABSTRACTING AND INDEXING AS TOPIC; ADVERSE DRUG REACTION REPORTING SYSTEMS; COHORT STUDIES; DATABASES, BIBLIOGRAPHIC; HUMANS; INFORMATION STORAGE AND RETRIEVAL; MEDLINE; NATIONAL LIBRARY OF MEDICINE (U.S.); PHARMACEUTICAL PREPARATIONS; REVIEW LITERATURE AS TOPIC; SUBJECT HEADINGS; UNITED STATES; VOCABULARY, CONTROLLED;

EID: 84865662824     PISSN: 15365050     EISSN: 15589439     Source Type: Journal    
DOI: 10.3163/1536-5050.100.2.012     Document Type: Article

References (60)

1. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol. 2001;1(7).
2. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions 5.1.0 [updated Mar 2011]. The Cochrane Collaboration; 2011.
3. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, Consort G. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004 Nov 16;141(10): 781-8.
4. Haidich A, Birtsou C, Dardavessis T, Tirodimos I, Arvanitidou M. The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol. 2011;64(2):124-35.
5. Yazici Y. Safety reporting in randomized clinical trials: a need for improvement. Bull NYU Hosp Jt Dis. 2009;67(2): 209-10.
6. Yiannakopoulou E, Damianou C, Bamia C, Papdopulos JS. Adequacy of safety data reporting in randomized clinical trials comparing coxibs with non selective NSAIDs. Epitheorese Klinikes Farmakologias Kai Farmakokinetikes. 2005; 23(1):42-3.
7. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JP. Safety reporting in randomized trials of mental health interventions. Am J Psychiatry. 2004;161(9):1692-7.
8. Ioannidis JPA, Lau J. Improving safety reporting from randomised trials. Drug Saf. 2002;25(2):77-84.
9. Neidig JL, Koletar SL. Safety reporting in clinical trials. JAMA. 2001 Apr 25;285(16):2077-8.
10. Kohl KS, Bonhoeffer J, Steering Committee of the Brighton Collaboration. Safety reporting in clinical trials. JAMA. 2001 Apr 25;285(16):2076-7; author reply: 7-8.
11. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001 Jan 24-31;285(4):437-43.
12. Chowers MY, Gottesman BS, Leibovici L, Pielmeier U, Andreassen S, Paul M. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. J Antimicrob Chemother. 2009 Aug;64(2):239-50.
13. Yazici Y. Some concerns about adverse event reporting in randomized clinical trials. Bull NYU Hosp Jt Dis. 2008;66(2):143-5.
14. Cheng CW, Bian ZX, Li YP, Moher D, Wu TX, Dagenais S, Li J, Li TQ. Transparently reporting adverse effects of traditional Chinese medicine interventions in randomized controlled trials. Zhong Xi Yi Jie He Xue Bao/J Chin Integr Med. 2008 Sep;6(9):881-6.
15. Bauer KA, Hammerman S, Rapoport B, Lacouture ME. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. Clin Colorectal Cancer. 2008 Sep;7(5):309-14.
16. Woodworth T, Furst DE, Alten R, Bingham C, Yocum D, Sloan V, Tsuji W, Stevens R, Fries J, Witter J, Johnson K, Lassere M, Brooks P. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol. 2007 Jun;34(6):1401-14.
17. Nuovo J, Sather C. Reporting adverse events in randomized controlled trials. Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):349-51.
18. Extermann M. More thoughts on the reporting of adverse events in cancer clinical trials. J Clin Oncol. 2007 Mar 1;25(7):918; author reply: 9.
19. Toenders WGM. Better reporting of adverse effects in clinical trials [Dutch]. Nederlands Tijdschrift voor Geneeskunde. 2006 Dec 23;150(51):2838.
20. Burfeind DB. Streamlining adverse event reporting in trials. Dermatol Nurs. 2006 Aug;18(4):381-2.
21. Anderson SJ. Some thoughts on the reporting of adverse events in phase II cancer clinical trials [comment]. J Clin Oncol. 2006 Aug 20;24(24):3821-2.
22. Sather C, Nuovo J. Reporting methods of adverse events in randomized controlled trials [abstract]. International Congress on Peer Review and Biomedical Publication: Chicago, IL, 16-18 Sep 2005. p. 54.
23. Lassere MND, Johnson KR, Woodworth TG, Furst DE, Fries JF, Kirwan JR, Tugwell PS, Day RO, Brooks PM. Challenges and progress in adverse event ascertainment and reporting in clinical trials. J Rheumatol. 2005 Oct;32(10):2030-2.
24. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22(1):19-22.
25. Liauw WS, Day RO. Adverse event reporting in clinical trials: room for improvement. Med J Aust. 2003 Oct 20;179(8):426-8.
26. Martin PJ, Antin JH, Weisdorf DJ, Paton V, Horowitz MM. Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(6):295-302.
27. Loke YKDS. Lack of detail and uniformity in the reporting of adverse drug reactions in randomized controlled trials: important implications for systematic reviews 9th Annual Cochrane Colloquium Abstracts; Lyon, France, Oct 2001.
28. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials: a systematic survey. BMC Clin Pharmacol. 2001;1(3).
29. Ethgen M, Boutron I, Steg PG, Roy C, Ravaud P. Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials [Internet]. 2009;10:29 [cited 9 Mar 2011].,http://www.trialsjournal.com/content/10/1/29/.
30. Ethgen M, Boutron I, Baron G, Giraudeau B, Sibilia J, Ravaud P. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med. 2005;143(1):20-5.
31. Ethgen M, Boutron I, Baron G, Giraudeau B, Sibilia J, Ravaud P. Reporting of harm in randomized controlled trials evaluating pharmacological and nonpharmacological treatments [abstract]. XIII Cochrane Colloquium; Melbourne, Australia; 22-26 Oct 2005. p. 97.
32. Papanikolaou P, Churchill R, Wahlbeck K, Ioannidis J. Reporting of harms in randomized trials of mental health interventions [abstract]. 12th Cochrane Colloquium; Bridging the Gaps: Ottawa, ON, Canada; 2-6 Oct 2004. p. 60-1.
33. Golder S, Loke Y, McIntosh HM. Room for improvement? a survey of the methods used in systematic reviews of adverse effects. BMC Med Res Methodol. 2006;6:3.
34. Golder S, Loke Y, McIntosh HM. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. J Clin Epidemiol. 2008;61:440-8.
35. Agbabiaka T, Pittler M, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf. 2009;32(8):637-47.
36. Albavera-Hernandez C, Rodriguez J, Idrovo A. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil. 2009;23(5):394-407.
37. Alghamdi AA, Moussa F, Fremes SE. Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? systematic review and meta-analysis. J Card Surg. 2007; 22(3):247-56.
38. Berlie H, Kalus J, Jaber L. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract. 2007;76(2):279-89.
39. Bonovas S, Sitaras N. Does pravastatin promote cancer in elderly patients? a meta-analysis. CMAJ. 2007;176(5):649-54.
40. Cao Y, Liu L, Liao C, Tan A, Gao F. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol. 2010;66(1):37-42.
41. Chavez-Tapia N, Tellez-Avila F, Bedogni G, Croce L, Masutti F, Tiribelli C. Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. BMC Gastroenterol. 2009;9(75).
42. Chen L, Ashcroft D. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2007;16(7):762-72.
43. Correll C. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46(6):687-700.
44. Dugoua J, Machado M, Zhu X, Chen X, Koren G, Einarson T. Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol Can. 2009;31(6):542-52.
45. Ford A, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14(48):7361-70.
46. Gehling M, Tryba M. Risks and side-effects of intrathecal morphine combined with spinal anaesthesia: a metaanalysis. Anaesthesia. 2009;64(6):643-51.
47. Johansson K, Neovius K, DeSantis S, Rössner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009;10(5):564-75.
48. Lakhdar R, Al-Mallah M, Lanfear D. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail. 2008;14(3):181-8.
49. Luykx J, Mason M, Ferrari M, Carpay J. Aremigraineurs at increased risk of adverse drug responses? a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009;85(3):283-8.
50. Mauri D, Valachis A, Polyzos I, Polyzos N, Kamposioras K, Pesce L. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat. 2009;116(3):433-9.
51. Morris T, Castrejon S, Devendra G, Gamst A. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest. 2007;132(4):1131-9.
52. Phillips C, Kashani A, Ko D, Francis G, Krumholz H. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007;167(18):1930-6.
53. Ravindran V, Rachapalli S, Choy E. Safety of mediumto long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology. 2009;48(7):807-11.
54. Rodrigo G, Nannini L, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008;133(5):1079-87.
55. Rodrigo G, Castro-Rodriguez J, Nannini L, Plaza Moral V, Schiavi E. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med. 2009;103(10):1421-9.
56. Siegel C, Marden S, Persing S, Larson R, Sands B. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874-81.
57. Silva M, Matthews M, Jarvis C, Nolan N, Belliveau P, Malloy M, Gandhi P. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253-60.
58. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12;298(10):1189-95.
59. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Sep 24;300(12): 1439-50.
60. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009 Feb 9;169(3):219-29.